# Manufacturing cost and time for living and radioactive medicines

Source: https://nuclide.cc/bottlenecks/b-manufacturing-cell-therapy/  
Nuclide record `b-manufacturing-cell-therapy` (Bottleneck). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Cell therapies take weeks to make for one patient and cost hundreds of thousands of dollars. Isotopes run short.

## Summary

Autologous CAR-T, TIL and TCR-T are one-batch-per-patient manufacturing: leukapheresis, shipping, transduction, expansion, release testing and return take several weeks, during which some patients progress or die, a proportion of products fail specification, and list prices run to several hundred thousand dollars before hospital costs. Only a small fraction of eligible patients receive approved CAR-T because of slot availability, referral and cost. Radioligand therapy has a different supply problem: lutetium-177 depends on a handful of reactors and enrichment sources, and actinium-225 for alpha therapy has been limited to a few curies a year worldwide from thorium-229 stocks, with accelerator and thorium-based production only now scaling. ADCs and bispecifics have complex biologics supply chains with a small number of contract manufacturers. In vivo CAR generation, allogeneic products, point-of-care and automated manufacturing, and new isotope production routes are the technical answers.

## Fields

- Kind: Bottleneck
- Last checked: 2026-09-08
- Stage: regulation-manufacturing
- Severity: major
- Metrics: Estimated total cost of CAR-T therapy including list price and management of adverse events (2018 US analysis): Up to ~US$500,000 per patient (Hernandez, Prasad & Gellad, JAMA Oncology 2018); Patients in ELIANA for whom tisagenlecleucel could not be manufactured: 7 of 92 enrolled (Maude et al., NEJM 2018); Historic global actinium-225 supply from thorium-229 stockpiles: ~63 GBq (1.7 Ci) per year (Robertson et al., Current Radiopharmaceuticals 2018)
- Causes: Autologous products are bespoke batches with no economies of scale.; Viral vector and GMP capacity are limited and expensive.; Actinium-225 has historically come only from decay of legacy thorium-229 held by a few government laboratories.; Lutetium-177 production depends on reactor time and enriched target material from few suppliers.; Release testing, cold-chain logistics and hospital accreditation add weeks and cost that no design optimisation removes.

## Sources

- Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018): https://doi.org/10.1001/jamaoncol.2018.0977
- Maude et al., Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia (ELIANA, NEJM 2018): https://doi.org/10.1056/NEJMoa1709866
- US Department of Energy Isotope Program: https://www.isotopes.gov/

## Connected records

- roadmaps: [Radiopharmaceutical roadmap: iodine → lutetium → actinium](https://nuclide.cc/roadmaps/radiopharma-roadmap/)
- ideas: [A coordinated reserve and shared schedule for the world's medical isotope reactors](https://nuclide.cc/ideas/idea-reg-medical-isotope-reactor-reserve/), [A global medical isotope supply observatory with forecasts and shortage alerts](https://nuclide.cc/ideas/idea-reg-isotope-supply-observatory/), [A university cyclotron network with shared regulatory files for new tracers](https://nuclide.cc/ideas/idea-fund-academic-radiopharma-pipeline/), [Build Western ytterbium-176 enrichment so lutetium-177 has more than one supplier](https://nuclide.cc/ideas/idea-reg-yb176-enrichment-capacity/), [Fund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211](https://nuclide.cc/ideas/idea-reg-alpha-emitter-portfolio/), [Recover legacy radium-226 sources worldwide as the feedstock for actinium-225](https://nuclide.cc/ideas/idea-reg-legacy-radium-recovery-ac225/), [Regional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit](https://nuclide.cc/ideas/idea-reg-ac225-accelerator-pharmacopoeia/), [Regional radiopharmacy hubs and harmonised transport rules for short-lived isotopes](https://nuclide.cc/ideas/idea-reg-regional-radiopharmacy-hubs/)
- isotopes: [Actinium-225](https://nuclide.cc/isotopes/ac-225/), [Lutetium-177](https://nuclide.cc/isotopes/lu-177/)
- indications: [Diffuse large B-cell lymphoma](https://nuclide.cc/indications/dlbcl/), [Neuroendocrine tumours](https://nuclide.cc/indications/neuroendocrine/), [Prostate cancer](https://nuclide.cc/indications/prostate/)
- technologies: [Actinium-225 supply: thorium stocks, accelerators and radium targets](https://nuclide.cc/technologies/actinium-225-supply/), [Radioligand therapy (beta emitters)](https://nuclide.cc/technologies/radioligand-therapy/), [Radiopharmaceutical GMP and releasing a drug that decays](https://nuclide.cc/technologies/radiopharmaceutical-gmp-release/), [Research reactors for medical isotopes (Mo-99, Lu-177, I-131)](https://nuclide.cc/technologies/research-reactor-isotope-production/), [Targeted alpha therapy](https://nuclide.cc/technologies/targeted-alpha-therapy/)
- drugs: [Actinium-225 PSMA agents](https://nuclide.cc/drugs/ac225-psma/), [Lutetium-177 dotatate](https://nuclide.cc/drugs/lutathera/), [Lutetium-177 vipivotide tetraxetan](https://nuclide.cc/drugs/pluvicto/)
- companies: [Curium](https://nuclide.cc/companies/curium/), [ITM Isotope Technologies Munich](https://nuclide.cc/companies/itm/), [Novartis](https://nuclide.cc/companies/novartis/), [Orano Med](https://nuclide.cc/companies/orano-med/), [TerraPower Isotopes](https://nuclide.cc/companies/terrapower-isotopes/)
- terms: [Alpha vs beta emitters](https://nuclide.cc/terms/alpha-vs-beta/), [Dosimetry](https://nuclide.cc/terms/dosimetry/), [Theranostics](https://nuclide.cc/terms/theranostics/)
- trials: [VISION](https://nuclide.cc/trials/vision/)
- bottlenecks: [Actinium-225 supply](https://nuclide.cc/bottlenecks/b-ac225-supply/)

---
JSON: https://nuclide.cc/api/v1/entities/b-manufacturing-cell-therapy.json